Bayabao, Alaizah D.
HRN: 21-95-47 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/12/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/14/2022
10/20/2022
IVT
400mg
Q6hrs
Hif; Status Epilepticus
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes